A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Authors
Category Primary study
ConferenceBlood
Year 2019
This article has no abstract
Epistemonikos ID: 1870ca26bb6c7b5f1bf008e61475df72b0227b65
First added on: Feb 11, 2025